News & Articles

New findings pave way to potentially improved assessment of measurable residual disease in AML patients

New service reduces project time from months to weeks for biopharma customers

The integrated solution offers deeper insight into therapy resistance and relapse, saving billions in drug development costs

The study leverages the Tapestri Platform to illustrate the single-cell atlas of acute myeloid leukemia (AML) with multi-omics, describing the clonality underlying therapeutic resistance

This strategic partnership aims to expand access to the Tapestri Platform for single-cell multiomics

Grant received to use the Mission Bio Tapestri Platform to improve the measurement of residual cancerous cells remaining post-treatment

Deal brings single-cell genomics to China and accelerates Mission Bio’s mission to predict and prevent cancer relapse on a global scale

Mission Bio announces the potential for more impactful, dynamic therapy development and application for those with acute myeloid leukemia (AML)

Single cell-sequencing technology will be used by Labcorp to support clinical trials and evaluate potential applications in clinical diagnostics and companion diagnostics development

In tandem, the company expands into Europe through partnerships with leading research and medical institutions to help them predict and prevent cancer relapse

Mission Bio closes Series A funding and launches Tapestri™ to accelerate the discovery, development and delivery of precision medicine